Cargando…

Development of Neurogenic Detrusor Overactivity after Thoracic Spinal Cord Injury Is Accompanied by Time-Dependent Changes in Lumbosacral Expression of Axonal Growth Regulators

Thoracic spinal cord injury (SCI) results in urinary dysfunction, which majorly affects the quality of life of SCI patients. Abnormal sprouting of lumbosacral bladder afferents plays a crucial role in this condition. Underlying mechanisms may include changes in expression of regulators of axonal gro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chambel, Sílvia Sousa, Ferreira, Ana, Oliveira, Raquel, Miranda, Rafael, Vale, Luís, Reguenga, Carlos, Schwab, Martin E., Cruz, Célia Duarte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368817/ https://www.ncbi.nlm.nih.gov/pubmed/35955811 http://dx.doi.org/10.3390/ijms23158667

Ejemplares similares

Botulinum Toxin in Neurogenic Detrusor Overactivity
por: D'Ancona, Carlos Arturo Levi, et al.
Publicado: (2012)

Inosine Improves Neurogenic Detrusor Overactivity following Spinal Cord Injury
por: Chung, Yeun Goo, et al.
Publicado: (2015)

Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity
por: Cho, Young Sam, et al.
Publicado: (2016)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin
por: Ferreira, Ana, et al.
Publicado: (2023)

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
por: Traini, Chiara, et al.
Publicado: (2019)

Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Hui, C, et al.
Publicado: (2016)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

AB206. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Chen, Hui, et al.
Publicado: (2016)

Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model
por: Biardeau, Xavier, et al.
Publicado: (2017)

Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury
por: Lombardi, Giuseppe, et al.
Publicado: (2017)

Sphingosine Kinase 1 urothelial expression is increased in patients with neurogenic detrusor overactivity
por: Ballouhey, Quentin, et al.
Publicado: (2015)

OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
por: Zhang, Rui, et al.
Publicado: (2015)

Adaptive changes of telocytes in the urinary bladder of patients affected by neurogenic detrusor overactivity
por: Traini, Chiara, et al.
Publicado: (2017)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies
por: Traini, Chiara, et al.
Publicado: (2019)

Axonal growth inhibitors and their receptors in spinal cord injury: from biology to clinical translation
por: Chambel, Sílvia Sousa, et al.
Publicado: (2023)

Semiconditional Electrical Stimulation of Pudendal Nerve Afferents Stimulation to Manage Neurogenic Detrusor Overactivity in Patients with Spinal Cord Injury
por: Lee, Young-Hee, et al.
Publicado: (2011)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
por: Wu, Shang-Jun, et al.
Publicado: (2019)

Conditional neuromodulation of neurogenic detrusor overactivity using transrectal stimulation in patients with spinal cord injury: A proof of principle study
por: Knight, Sarah Louise, et al.
Publicado: (2017)

Investigating Urine Biomarkers in Detrusor Underactivity and Detrusor Overactivity with Detrusor Underactivity Patients
por: Jiang, Yuan-Hong, et al.
Publicado: (2023)

Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis
por: Li, Guang-Ping, et al.
Publicado: (2018)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
por: Zhou, Xin, et al.
Publicado: (2015)

Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity – A Retrospective Cohort Study
por: Krebs, Jörg, et al.
Publicado: (2020)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2022)

Molecular and functional characterization of detrusor PDGFRα positive cells in spinal cord injury-induced detrusor overactivity
por: Lee, Ken, et al.
Publicado: (2021)

Gabapentin add-on therapy for patients with spinal cord injury associated neurogenic overactive detrusors that are unresponsive to combined anticholinergic and beta-3 adrenergic therapy
por: Cakici, Ozer Ural, et al.
Publicado: (2021)

Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis
por: Yuan, Hejia, et al.
Publicado: (2017)

BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study
por: Maignel, Jacquie, et al.
Publicado: (2022)

CONCOMITANT DETRUSOR AND EXTERNAL URETHRAL SPHINCTER BOTULINUM TOXIN-A INJECTIONS IN MALE SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA
por: HUANG, Yu-Hui, et al.
Publicado: (2022)

Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
por: Tarcan, Tufan, et al.
Publicado: (2014)

Neurogenic Detrusor Overactivity Is Associated with Decreased Expression and Function of the Large Conductance Voltage- and Ca(2+)-Activated K(+) Channels
por: Hristov, Kiril L., et al.
Publicado: (2013)

Characterization of upper lamina propria interstitial cells in bladders from patients with neurogenic detrusor overactivity and bladder pain syndrome
por: Gevaert, Thomas, et al.
Publicado: (2011)

Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity
por: Leitner, Lorenz, et al.
Publicado: (2016)

Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study
por: Baka‐Ostrowska, Małgorzata, et al.
Publicado: (2021)

Percutaneous tibial nerve stimulation in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: a historically controlled study
por: Carilli, Marco, et al.
Publicado: (2023)

AB204. Repeated intradetrusor botulinum toxin type A injections are still effective for patients with neurogenic detrusor overactivity secondary to spinal cord injury in China
por: Chen, Hui, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kbts6fgve40bmv1gkmnjh3j6m7